Source: International Congress 2019 – Translational aspects of idiopathic pulmonary fibrosis
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
K. Roach (Leicester, United Kingdom), E. Castells (Leicester, United Kingdom), P. Tongue (Leicester, United Kingdom), G. Elliott (Leicester, United Kingdom), H. Marshall (Leicester, United Kingdom), M. Richardson (Leicester, United Kingdom), L. Chachi (Leicester, United Kingdom), S. Mason (Leicester, United Kingdom), A. Sutcliffe (Leicester, United Kingdom), P. Bradding (Leicester, United Kingdom). Evaluation of Idiopathic Pulmonary Fibrosis therapies, Pirfenidone and Nintedanib, in a Human Experimental Model of Fibrosis. 5376

Member's Comments

No comment yet.

Related content which might interest you: A new Humanized Mouse Model for Idiopathic Pulmonary Fibrosis and Effects of Nintedanib Treatment Source: International Congress 2018 – Progress in basic and translational research on idiopathic interstitial pneumonias Year: 2018 Treatment of Idiopathic Pulmonary Fibrosis Source: Guideline 2015 Year: 2015 Treatment of Idiopathic Pulmonary Fibrosis - Evidence to Decision Frameworks Source: Guideline 2015 Year: 2015 Treatment of Idiopathic Pulmonary Fibrosis - Executive Summary Source: Guideline 2015 Year: 2015 Tele-rehabilitation program in Idiopathic Pulmonary Fibrosis Source: International Congress 2019 – M-health/e-health I Year: 2019 Exploring Efficacy and Safety of Oral Pirfenidone for Progressive, non-IPF Lung Fibrosis (RELIEF-Study) Source: International Congress 2017 – New ideas for the management of chronic lung diseases Year: 2017 Clinical Correlates of Physical Activity in Idiopathic Pulmonary Fibrosis (IPF) Source: International Congress 2019 – Pulmonary rehabilitation for non-obstructive lung diseases Year: 2019 Prevalence and Characteristics of Patients Receiving Antifibrotic Therapy for Idiopathic Pulmonary Fibrosis Source: Virtual Congress 2020 – Real life in the field of idiopathic pulmonary fibrosis: treatments and registries Year: 2020 Late Breaking Abstract - BBT-877, a Potent Autotaxin Inhibitor in Clinical Development to Treat Idiopathic Pulmonary Fibrosis Source: International Congress 2019 – Translational aspects of idiopathic interstitial pneumonia Year: 2019 Development Of A Machine Learning Combination With Deep Learning For Diagnosing Idiopathic Pulmonary Fibrosis In Chronic Interstitial Lung Disease Source: Virtual Congress 2020 – Predictive markers of progression in connective tissue disease-associated interstitial lung disease and hypersensitivity pneumonitis Year: 2020 LATE-BREAKING ABSTRACT: Efficacy of Pirfenidone for Idiopathic Pulmonary Fibrosis (IPF): an Italian real life study Source: International Congress 2014 – IPF and surroundings Year: 2014 Histopathologic and Molecular Analysis of Idiopathic Pulmonary Fibrosis Lungs from Patients Treated with Pirfenidone or Nintedanib Source: International Congress 2018 – News on the diagnosis of idiopathic interstitial pneumonia Year: 2018 Potential benefits of Nordic Walking for Idiopathic Pulmonary Fibrosis Source: International Congress 2019 – Treatment and prognosis of idiopathic interstitial pneumonia Year: 2019 Late Breaking Abstract - Long-term Effect of Pulmonary Rehabilitation under Nintedanib treatment in Idiopathic Pulmonary Fibrosis (FITNESS study) Source: Virtual Congress 2021 – ALERT: Asthma in adult, in children and ILDs Year: 2021 Association between Pulmonary Infections and the Prognosis in Patients with Idiopathic Pulmonary Fibrosis Source: Virtual Congress 2021 – Interstitial lung disease around the world Year: 2021 Clinical Features and Prognosis of Acute exacerbation of Connective Tissue Diseases Associated Pulmonary Fibrosis------ Comparision with Idiopathic Pulmonary Fibrosis Source: International Congress 2017 – The spectrum of CTDs: from pathogenesis to treatment Year: 2017 Breath Biomarkers in Idiopathic Pulmonary Fibrosis: A Systematic Review Source: International Congress 2018 – News on the diagnosis of idiopathic interstitial pneumonia Year: 2018 Epidemiology of Idiopathic Pulmonary Fibrosis in Australia Source: Virtual Congress 2021 – Interstitial lung disease around the world Year: 2021 Is Pulmonary Rehabilitation A Savior In Idiopathic Pulmonary Fibrosis? Source: Virtual Congress 2020 – News on diagnosis and therapy of idiopathic pulmonary fibrosis Year: 2020 Sensitivity analyses from the INPULSIS™ trials of nintedanib Source: International Congress 2014 – Clinical trials in IPF Year: 2014